Godwin Tusabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Godwin Tusabe has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Alisen Ayitewala
Department of National Health Laboratories and Diagnostics Services, Central Public Health Laboratories, Ministry of Health, Kampala Uganda
5 shared publications - Gerald Mboowa
College of Health Sciences, Makerere University, Kampala, Uganda
5 shared publications - Isaac Ssewanyana
Infectious Diseases Research Collaboration, Kampala, Uganda
5 shared publications - Ivan Sserwadda
Department of Immunology and Molecular Biology, College of Health Sciences, School of Biomedical Sciences Kampala P.O. Box 7072 Makerere University
5 shared publications - Stephen Kanyerezi
Department of National Health Laboratory and Diagnostics Services, Central Public Health Laboratories (NHLDS-CPHL), Ministry of Health, P.O. Box 7272, Kampala, Uganda
5 shared publications - Susan Nabadda
Department of National Health Laboratories and Diagnostics Services, Central Public Health Laboratories, Ministry of Health, Uganda
5 shared publications
Latest Publications
- Open Access
- 16 December 2025
- Published by MDPI AG in Preprints.org
Harnessing Genomics for Public Health: Use-Case Insights from Uganda
Genomic technologies are transforming infectious disease surveillance and control, particularly in resource-limited settings such as Uganda. This review examines ongoing efforts by the Department of National Health Laboratory and Diagnostic Services - Central Public Health Laboratories (NHLDS-CPHL) to integrate genomics into public health strategies. We highlight key advancements, lessons learned, and opportunities, including expanded genomic testing capacity, localized bioinformatics infrastructure, and reinforcement of surveillance systems. Through use-case studies on COVID-19, HIV/AIDS, malaria, Ebola, Mpox, rotavirus, and cholera, we demonstrate the impact of genomics on improving diagnostic accuracy, disease monitoring and outbreak response, identifying drug resistance, and informing targeted public health interventions. Despite these successes, challenges, including but not limited to infrastructure gaps, funding constraints, and ethical considerations, remain, underscoring the need for policy, regulation, and capacity enhancement as well as global collaboration to effectively address these obstacles. Lessons learned from these efforts provide valuable recommendations for optimizing and sustaining genomic programs in low-resource settings. By leveraging genomics, Uganda can further strengthen its ability to detect, monitor, and respond to emerging and re-emerging health threats, ultimately enhancing disease control measures and public health resilience.
- 16 December 2025
- Published by MDPI AG in Preprints.org
Open AccessHarnessing Genomics for Public Health: Use-Case Insights from Uganda
Genomic technologies are transforming infectious disease surveillance and control, particularly in resource-limited settings such as Uganda. This review examines ongoing efforts by the Department of National Health Laboratory and Diagnostic Services - Central Public Health Laboratories (NHLDS-CPHL) to integrate genomics into public health strategies. We highlight key advancements, lessons learned, and opportunities, including expanded genomic testing capacity, localized bioinformatics infrastructure, and reinforcement of surveillance systems. Through use-case studies on COVID-19, HIV/AIDS, malaria, Ebola, Mpox, rotavirus, and cholera, we demonstrate the impact of genomics on improving diagnostic accuracy, disease monitoring and outbreak response, identifying drug resistance, and informing targeted public health interventions. Despite these successes, challenges, including but not limited to infrastructure gaps, funding constraints, and ethical considerations, remain, underscoring the need for policy, regulation, and capacity enhancement as well as global collaboration to effectively address these obstacles. Lessons learned from these efforts provide valuable recommendations for optimizing and sustaining genomic programs in low-resource settings. By leveraging genomics, Uganda can further strengthen its ability to detect, monitor, and respond to emerging and re-emerging health threats, ultimately enhancing disease control measures and public health resilience.
- Open Access
Targeted Metagenomics Reveals Hidden Chickenpox Epidemic Amid Mpox Surveillance in Uganda
In regions where both Mpox virus (MPXV) and varicella zoster virus (VZV) are co-circulating, overlapping clinical manifestations can complicate clinical diagnosis. During the MPXV outbreak declared in Uganda on July, 2024, symptomatic suspected cases tested PCR negative for Mpox. To determine the cause of symptoms, we employed metagenomic sequencing with a targeted Viral Surveillance panel in 284 Mpox negative samples. VZV was identified as the predominant pathogen in 86% of MPXV-negative cases, suggesting a concurrent chickenpox surge. Using the VaricellaGen pipeline for variant calling, clade typing, and phylogeny, 118 (42%) samples that achieved ≥70% genome coverage were of clade 5 based on the single-nucleotide polymorphism (SNP) dataset. This data confirms co-circulation of chickenpox during the Mpox outbreak in Uganda. Our results underscore the need for laboratory confirmation of Mpox and the inclusion of VZV in the testing algorithm during the Mpox outbreak.
Open AccessTargeted Metagenomics Reveals Hidden Chickenpox Epidemic Amid Mpox Surveillance in Uganda
In regions where both Mpox virus (MPXV) and varicella zoster virus (VZV) are co-circulating, overlapping clinical manifestations can complicate clinical diagnosis. During the MPXV outbreak declared in Uganda on July, 2024, symptomatic suspected cases tested PCR negative for Mpox. To determine the cause of symptoms, we employed metagenomic sequencing with a targeted Viral Surveillance panel in 284 Mpox negative samples. VZV was identified as the predominant pathogen in 86% of MPXV-negative cases, suggesting a concurrent chickenpox surge. Using the VaricellaGen pipeline for variant calling, clade typing, and phylogeny, 118 (42%) samples that achieved ≥70% genome coverage were of clade 5 based on the single-nucleotide polymorphism (SNP) dataset. This data confirms co-circulation of chickenpox during the Mpox outbreak in Uganda. Our results underscore the need for laboratory confirmation of Mpox and the inclusion of VZV in the testing algorithm during the Mpox outbreak.
- Open Access
- 1 July 2024
- Published by Microbiology Society in Access Microbiology
- Vol. 6 (7) , 000815.v3
HIV-DRIVES: HIV drug resistance identification, variant evaluation, and surveillance pipeline
The global prevalence of resistance to antiviral drugs combined with antiretroviral therapy (cART) emphasizes the need for continuous monitoring to better understand the dynamics of drug-resistant mutations to guide treatment optimization and patient management as well as check the spread of resistant viral strains. We have recently integrated next-generation sequencing (NGS) into routine HIV drug resistance (HIVDR) monitoring, with key challenges in the bioinformatic analysis and interpretation of the complex data generated, while ensuring data security and privacy for patient information. To address these challenges, here we present HIV-DRIVES (HIV Drug Resistance Identification, Variant Evaluation, and Surveillance), an NGS-HIVDR bioinformatics pipeline that has been developed and validated using Illumina short reads, FASTA, and Sanger ab1.seq files.
- 1 July 2024
- Published by Microbiology Society in Access Microbiology
- Vol. 6 (7) , 000815.v3
Open AccessHIV-DRIVES: HIV drug resistance identification, variant evaluation, and surveillance pipeline
The global prevalence of resistance to antiviral drugs combined with antiretroviral therapy (cART) emphasizes the need for continuous monitoring to better understand the dynamics of drug-resistant mutations to guide treatment optimization and patient management as well as check the spread of resistant viral strains. We have recently integrated next-generation sequencing (NGS) into routine HIV drug resistance (HIVDR) monitoring, with key challenges in the bioinformatic analysis and interpretation of the complex data generated, while ensuring data security and privacy for patient information. To address these challenges, here we present HIV-DRIVES (HIV Drug Resistance Identification, Variant Evaluation, and Surveillance), an NGS-HIVDR bioinformatics pipeline that has been developed and validated using Illumina short reads, FASTA, and Sanger ab1.seq files.
- Open Access
- 21 June 2024
- Published by Microbiology Society
- p. 000815.v2
HIV-DRIVES: HIV Drug Resistance Identification, Variant Evaluation, & Surveillance Pipeline
The global prevalence of resistance to antiviral drugs combined with antiretroviral therapy (cART) emphasizes the need for continuous monitoring to better understand the dynamics of drug-resistant mutations to guide treatment optimization and patient management as well as check the spread of resistant viral strains. We have recently, integrated next-generation sequencing (NGS) into routine HIV drug resistance (HIVDR) monitoring, with key challenges in the bioinformatic analysis and interpretation of the complex data generated while ensuring data security and privacy of patient information. To address these challenges, here, we present HIV-DRIVES (HIV Drug Resistance Identification, Variant Evaluation, and Surveillance), an NGS-HIVDR bioinformatics pipeline that has been developed and validated using Illumina short-reads, FASTA, and Sanger ab1.seq files.
- 21 June 2024
- Published by Microbiology Society
- p. 000815.v2
Open AccessHIV-DRIVES: HIV Drug Resistance Identification, Variant Evaluation, & Surveillance Pipeline
The global prevalence of resistance to antiviral drugs combined with antiretroviral therapy (cART) emphasizes the need for continuous monitoring to better understand the dynamics of drug-resistant mutations to guide treatment optimization and patient management as well as check the spread of resistant viral strains. We have recently, integrated next-generation sequencing (NGS) into routine HIV drug resistance (HIVDR) monitoring, with key challenges in the bioinformatic analysis and interpretation of the complex data generated while ensuring data security and privacy of patient information. To address these challenges, here, we present HIV-DRIVES (HIV Drug Resistance Identification, Variant Evaluation, and Surveillance), an NGS-HIVDR bioinformatics pipeline that has been developed and validated using Illumina short-reads, FASTA, and Sanger ab1.seq files.
- Open Access
- 22 March 2024
- Published by Microbiology Society
- p. 000815.v1
HIV-DRIVES: HIV Drug Resistance Identification, Variant Evaluation, & Surveillance Pipeline
The global prevalence of resistance to antiviral drugs combined with antiretroviral therapy (cART) emphasizes the need for continuous monitoring to better understand the dynamics of drug-resistant mutations to guide treatment optimization and patient management as well as check the spread of resistant viral strains. We have recently, integrated next-generation sequencing (NGS) into routine HIV drug resistance (HIVDR) monitoring, with key challenges in the bioinformatic analysis and interpretation of the complex data generated while ensuring data security and privacy of patient information. To address these challenges, here, we present HIV-DRIVES (HIV Drug Resistance Identification, Variant Evaluation, and Surveillance), an NGS-HIVDR bioinformatics pipeline that has been developed and validated using Illumina short-reads, FASTA, and Sanger ab1.seq files.
- 22 March 2024
- Published by Microbiology Society
- p. 000815.v1
Open AccessHIV-DRIVES: HIV Drug Resistance Identification, Variant Evaluation, & Surveillance Pipeline
The global prevalence of resistance to antiviral drugs combined with antiretroviral therapy (cART) emphasizes the need for continuous monitoring to better understand the dynamics of drug-resistant mutations to guide treatment optimization and patient management as well as check the spread of resistant viral strains. We have recently, integrated next-generation sequencing (NGS) into routine HIV drug resistance (HIVDR) monitoring, with key challenges in the bioinformatic analysis and interpretation of the complex data generated while ensuring data security and privacy of patient information. To address these challenges, here, we present HIV-DRIVES (HIV Drug Resistance Identification, Variant Evaluation, and Surveillance), an NGS-HIVDR bioinformatics pipeline that has been developed and validated using Illumina short-reads, FASTA, and Sanger ab1.seq files.